FDA Approves ASCENIV™ (formerly referred to as RI-002), A Novel Intravenous Immune Globulin
See the Press Release
ADMA Biologics is a biopharmaceutical company relentlessly committed to creating superior products for immunodeficient patients at risk for infection. It is our devotion to this underserved population that fuels us, and our hands-on approach to production and development that sets us apart.
ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results
ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results:READ MOREADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®
ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®:READ MOREADMA Biologics to Present at Upcoming Investor Conferences
ADMA Biologics to Present at Upcoming Investor Conferences:READ MORE